# Capstan Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/capstan-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.capstantx.com
- Total disclosed funding: $253M
- Latest round: Series B (Mar 5, 2024)
- Investors on record: 15

## About

Based in California, US, and founded in 2021, Capstan Therapeutics Inc. operates as a biotech company that provides the development and advancement of vivo cell-based engineering therapies. Based in the US, Capstan Therapeutics Inc. is a biotechnology company that provides the development and advancement of cell-based therapies to treat patients across multiple disease categories like oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. Based in California, US, and founded in 2021, Capstan Therapeutics Inc. operates as a biotech company that provides the development and advancement of vivo cell-based engineering therapies In June 2025, AbbVie agreed to acquire Capstan Therapeutics Inc. from Sofinnova Partners, Perceptive Advisors, Mubadala Capital, Johnson & Johnson Innovation, Forbion, Polaris Partners, Pfizer Venture Investments, Leaps by Bayer, Eli Lilly & Company, Bristol-Myers Squibb Company, Alexandria Venture Investments, Vida Ventures, RA Capital Management, OrbiMed Advisors, Novartis Venture Fund and Maasinvest for approximately USD 2.1 billion in cash. The company combines vivo cell therapy with genetic medicines to develop new treatment options for patients across oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. Capstan’s precision vivo engineering technology platform is comprised of targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body, non-viral delivery systems, cell type-specific targeting molecules, and disease-specific payload design through in vivo generated CAR T cells. Capstan Therapeutics generates revenue by developing and licensing its proprietary CellSeeker targeted lipid nanoparticle platform, which delivers RNA payloads such as mRNA or gene editing tool to reprogram specific cell types in vivo. This technology enables the creation of off-the-shelf CAR-T therapies and other treatments for autoimmune diseases, oncology, fibrosis, and monogenic blood disorders. The June 2025 acquisition will help the company to accelerate clinical development, expanding resources and enhancing its platform’s reach in autoimmune and cell therapy markets through AbbVie’s global infrastructure.

## Funding rounds

- Series B, Mar 5, 2024, $88M — OrbiMed Advisors, Sofinnova Partners, Polaris Partners, Novartis Venture Fund, Alexandria Venture Investments, Johnson & Johnson Innovation, Forbion, Pfizer Venture Investments, Eli Lilly & Company, RA Capital Management, Bristol-Myers Squibb Company, Perceptive Advisors, Mubadala Capital, Vida Ventures, Leaps by Bayer
- Series A, Sep 14, 2022, $102M — OrbiMed Advisors, Polaris Partners, Novartis Venture Fund, Alexandria Venture Investments, Pfizer Venture Investments, Eli Lilly & Company, RA Capital Management, Bristol-Myers Squibb Company, Vida Ventures, Leaps by Bayer
- Seed, Nov 1, 2021, $63M — OrbiMed Advisors, Novartis Venture Fund, RA Capital Management, Vida Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Seed, Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Seed, Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Seed, Series A, Series B
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Seed, Series A, Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A, Series B
- Eli Lilly & Company — Series A, Series B
- Bristol-Myers Squibb Company — Series A, Series B
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A, Series B
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series B